A recent study reveals that patients who come off popular weight-loss injections like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who halt traditional lifestyle plans.
Published data in a major health publication shows that while obese people can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month after stopping.
"Individuals buying such treatments must be aware of the risk of quick rebound weight gain when the treatment ends," stated expert Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original mass in about one and a half years.
Analyzing Approaches
The research, which looked at 37 of studies involving over 9,000 of patients, contrasted the results of these new drugs with conventional dieting.
Researchers note that individuals who lose weight through diet and exercise generally see a more gradual creep back—approximately 100 grams monthly—once they finish.
Understanding the Fast Rebound
Nutrition scientists believe the way of the drugs explains the heightened regain.
These medications copy a body's own chemical called GLP-1, which controls appetite.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication means appetite is uncontrolled, making binge eating far more likely."
An Ongoing Disease?
Health authorities recommend the jabs for people with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, due to the significant potential of weight regain, the therapy should be considered life-long.
This opinion is reinforced by pharmaceutical companies, who state that the results "underscore the persistent nature of obesity," similar to managing conditions like hypertension.
User Testimonies
People who have come off the medication report a sudden resurgence of appetite.
"I experienced a switch activating and you become ravenous," recalled one woman.
The struggle is worsened if users have not adopted sustainable dietary or behavioural modifications during treatment.
Widespread Use
Recent estimates suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is higher among females than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
Ultimately, researchers caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on combined behavioural changes.
